- Home
- AXS vs ROIV Comparison
AXS vs ROIV Comparison
Compare AXS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXS
- ROIV
- Stock Information
- Founded
- AXS 2001
- ROIV 2014
- Country
- AXS Bermuda
- ROIV United Kingdom
- Employees
- AXS N/A
- ROIV N/A
- Industry
- AXS Property-Casualty Insurers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AXS Finance
- ROIV Health Care
- Exchange
- AXS Nasdaq
- ROIV Nasdaq
- Market Cap
- AXS 8.1B
- ROIV 8.4B
- IPO Year
- AXS N/A
- ROIV N/A
- Fundamental
- Price
- AXS $100.99
- ROIV $10.91
- Analyst Decision
- AXS Strong Buy
- ROIV Buy
- Analyst Count
- AXS 9
- ROIV 4
- Target Price
- AXS $107.75
- ROIV $17.50
- AVG Volume (30 Days)
- AXS 549.9K
- ROIV 5.5M
- Earning Date
- AXS 04-30-2025
- ROIV 05-29-2025
- Dividend Yield
- AXS 1.74%
- ROIV N/A
- EPS Growth
- AXS 54.31
- ROIV N/A
- EPS
- AXS 10.08
- ROIV N/A
- Revenue
- AXS $6,055,200,000.00
- ROIV $122,585,000.00
- Revenue This Year
- AXS $4.15
- ROIV N/A
- Revenue Next Year
- AXS $8.03
- ROIV N/A
- P/E Ratio
- AXS $10.02
- ROIV N/A
- Revenue Growth
- AXS 5.79
- ROIV 140.04
- 52 Week Low
- AXS $68.02
- ROIV $8.73
- 52 Week High
- AXS $103.85
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AXS 57.25
- ROIV 52.03
- Support Level
- AXS $98.40
- ROIV $10.58
- Resistance Level
- AXS $103.85
- ROIV $11.77
- Average True Range (ATR)
- AXS 1.83
- ROIV 0.33
- MACD
- AXS 0.15
- ROIV -0.04
- Stochastic Oscillator
- AXS 53.34
- ROIV 28.57
About AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.